Long non-coding RNAs (lncRNAs) play important roles in the maintenance of metabolic homeostasis. Recently, many studies have suggested that lncRNAs, such as Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1) and Imprinted Maternally Expressed Transcript (H19), might participate in the pathogenesis of metabolic disorders such as obesity. We conducted a case-control study with 150 Russian children and adolescents aged between 5 and 17 years old in order to assess the statistical association between the single nucleotide polymorphisms (SNPs) rs3200401 in MALAT1 and rs217727 in H19, and the risk of developing obesity in this population. We further explored the possible association of rs3200401 and rs217727 with BMI Z-score and insulin resistance. The MALAT1 rs3200401 and H19 rs217727 SNPs were genotyped using Taqman SNP genotyping assay. The MALAT1 rs3200401 SNP was identified as a risk factor for childhood obesity (p < 0.05) under the dominant and allelic models, and the CT heterozygous genotype was associated with the risk of increased BMI and with insulin resistance. The H19 rs217727 SNP had no significant association with obesity risk (all p > 0.05). Our findings thus suggest that MALAT1 SNP rs3200401 is a potential indicator of obesity susceptibility and pathogenesis in children and adolescents.
В последние годы накапливается все больше данных о роли длинных некодирующих РНК (lncRNAs) в развитии ожирения. H19 представляет собой импринтированный ген, который кодирует lncRNA. Роль гена H19 и его дифференциальная экспрессия при ожирении остаются малоизученными. Результаты исследований экспрессии H19 при ожирении в разных тканях (гепатоцитах, адипоцитах и мышцах) показали ее разнонаправленность в различных исследованиях. Кроме этого, потенциальный регуляторный механизм экспрессии H19 до сих пор полностью неясен. Всестороннее понимание функции и регуляции H19 может обеспечить перспективы применения lncRNA H19 как диагностического биомаркера и терапевтической мишени при ожирении. Цель: обзор и обобщение данных литературы о механизмах регуляции экспрессии гена H19 и его роли в развитии ожирения. Методы. Поиск литературы по исследованию регуляции и роли гена H19 и lncRNA H19 при ожирении проводили в базах данных Pubmed, GoogleAcademy и E-library, в период с 2000 по 2022 гг. Результаты. В обзоре рассмотрены механизмы участия lncRNA H19 в регуляции метаболизма углеводов и жиров у человека и мыши и их роль в развитии ожирения. Впервые, основываясь на анализе данных литературы, высказано предположение о потенциальной роли гипоксии в регуляции экспрессии H19 у лиц с ожирением. Выводы. Ген H19 и lncRNA H19 играют важную роль в развитии ожирения путем регуляции экспрессии генов, отвечающих за метаболизм глюкозы и липидов. Гипоксия, возникающая при ожирении, возможно, играет роль в дифференциальной аберрантной экспрессии H19. Понимание механизмов регуляции экспрессии гена H19 при ожирении обеспечивает базу для разработки эффективных диагностических и терапевтических стратегий для лечения и контроля ожирения. Background. Accumulating evidences approve the role of long non-coding RNAs (lncRNAs) in the maintenance of metabolic homeostasis; dysregulation of certain lncRNAs induces the progression of metabolic syndromes such as obesity. H19 is an imprinted maternally-expressed gene, codes for a lncRNA molecule. Role of H19 and its differential expression in obesity remain poorly understood. Findings related to H19 upregulation or downregulation in metabolic organs of obese patients showed discrepancy among different studies, and the potential regulatory mechanism behind this still unclear. A comprehensive characterization of the function and regulation of H19 can provide prospective basis for the development of potential therapeutic and diagnostic method to manage obesity. Aim. Summarize the roles of lncRNA H19 in developing obesity, and the potential regulatory mechanisms of its expression. Methods. Conducting a theoretical literature search for articles investigating the role and regulation of H19 in obesity. Search was done in the databases: Pubmed, Google Academy and E-library, in the period from 2000 to 2022 Results. We illustrated the role of lncRNA H19 in carbohydrates and lipid metabolism. Based on our analysis of the published literature, we proposed a potential role of hypoxia in regulating expression of H19 in obese individuals. Conclusion. The lncRNA H19 plays an important role in the development of obesity by regulating the expression of genes responsible for glucose and lipid metabolism. Hypoxia, resulting from a chronic low-grade inflammation related to obesity may regulate the differential aberrant expression of H19, This proposal should become a relevant problem for future researches in order to understand the regulatory mechanism of H19 expression in obesity, for further development of effective methods in obesity management and prevention.
Background: Hormonal imbalance and metabolic inefficiency are hallmarks of the common complicated endocrine condition known as polycystic ovary syndrome (PCOS). Long non-coding RNAs (lncRNAs) have emerged as critical regulators of gene expression and cellular processes in various diseases, including PCOS. This study aims to investigate the relationship between specific polymorphisms in the lncRNA genes MALAT1 (rs3200401) and NEAT1 (rs674485) and the likelihood of developing PCOS. A case-control study was conducted involving PCOS women and control undergoing in vitro fertilization (IVF) at the Center for Human Reproduction and IVF in Rostov-on-Don, Russia. Genotyping was conducted using an allele-specific real-time PCR approach. Results: Our results suggest a possible association between MALAT1 rs3200401 and increased PCOS risk at the allelic level. While the difference observed in the GA genotype of NEAT1 rs674485 did not reach statistical significance and required confirmation in larger cohorts. In addition, deviation from the Hardy–Weinberg equilibrium was observed in control groups, which may reflect sample size limitations or population-specific effects. Bioinformatic analyses indicated that both variants may potentially influence the lncRNA secondary structure and microRNA binding sites; however, these findings are computational predictions and require experimental validation. Conclusion: These findings underscore the potential of MALAT1 and NEAT1 genetic variants as biomarkers and therapeutic targets in PCOS.